NASDAQ: SANA - Sana Biotechnology, Inc.

Yield per half year: -54.85%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Sana Biotechnology, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc., биотехнологическая компания, специализируется на использовании искусственных клеток в качестве лекарств. Компания разрабатывает платформы клеточной инженерии in vivo и ex vivo для различных терапевтических областей с неудовлетворенными потребностями в лечении, включая онкологию, диабет, расстройства центральной нервной системы, сердечно-сосудистые заболевания, генетические нарушения и другие. Sana Biotechnology, Inc. ранее была известна как FD Therapeutics, Inc. и сменила свое название на Sana Biotechnology, Inc. в сентябре 2018 года.

more details
Компания была зарегистрирована в 2018 году со штаб-квартирой в Сиэтле, штат Вашингтон.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-02-04
ISIN US7995661045
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.sana.com
Цена ао 2.07
Change price per day: 0% (1.77)
Change price per week: +7.27% (1.65)
Change price per month: -2.21% (1.81)
Change price per 3 month: -47.63% (3.38)
Change price per half year: -54.85% (3.92)
Change price per year: -79.7% (8.72)
Change price per 3 year: -59.68% (4.39)
Change price per year to date: +8.59% (1.63)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.08 5
P/E 0 0
EV/EBITDA -2.89 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -50.11 0
ROE, % -98.52 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3529 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 81.15 9
Yield EPS, % 45.6 6
Total: 7
More

Institutions Volume Share, %
Flagship Pioneering Inc. 25001856 11.34
FMR, LLC 15751291 7.15
Canada Pension Plan Investment Board 10175000 4.62
Baillie Gifford and Company 10150017 4.6
Vanguard Group Inc 9797084 4.44
Blackrock Inc. 8469222 3.84
State Street Corporation 5908687 2.68
Price (T.Rowe) Associates Inc 3594025 1.63
Crestline Management, L.P. 3365624 1.53
Alphabet Inc. 2812500 1.28

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.0919 426.34 0.8416
Principal Healthcare Innovators ETF 0.0919 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.01678 596.94 0.72598
iShares Morningstar Small-Cap ETF 0.01096 391.25 1.60498
iShares Morningstar Small-Cap Value ETF 0.00549 197.28 2.50476
0.04446.061.3



Head Job title Payment Year of birth
Mr. Nathan Hardy M.B.A. Executive VP & CFO 683.49k 1976 (49 years)
Dr. Edward Rebar Ph.D. Head of Cell Engineering N/A 1968 (57 years)
Ms. Robin Andrulevich Executive VP & Chief People Officer N/A 1966 (59 years)
Dr. Steven D. Harr M.D. President, CEO & Director 1.04M 1970 (55 years)
Mr. Paul Brunetta M.D. Senior VP and Head of Clinical & Translational Science N/A
Mr. Bernard J. Cassidy J.D. Executive VP, General Counsel & Corporate Secretary 491.39k 1955 (70 years)
Mr. Christian Hordo M.B.A. Executive VP & Chief Business Officer 485.03k 1983 (42 years)
Dr. Sonja Schrepfer M.D., Ph.D. Senior VP & Head of Hypoimmune Platform N/A 1975 (50 years)
Mr. Snehal Patel Senior VP & Chief Technical Officer
Dr. Dhavalkumar D. Patel M.D., Ph.D. Executive VP & Chief Scientific Officer 1961 (64 years)

Address: United States, Seattle, 188 East Blaine Street - open in Google maps, open in Yandex maps
Website: https://www.sana.com